Lates News

Today, reporters learned from Sanofi that the rumor circulating in the market about Sanofi stopping the supply of Praluent (alirocumab injection) in the Chinese market is true. Sanofi stated that the supply was halted due to global supply issues and the company's upgrade of its cardiovascular product strategy in China: the company reached a cooperation agreement with Shanghai Pharmaceuticals' Aficamten at the end of last year for the Greater China BD partnership, and recently announced the acquisition of the rights of Viacin's investigational drug Pulsirlan Sodium injection for the Greater China region. The company's cardiovascular product strategy in China will be upgraded as a whole. Sanofi also emphasized that they will continue to provide products in different areas to meet the needs of domestic patients. (Finance and Economics Society)